SLC27A2 and neoplasm: Mouse and human PMN-MDSCs upregulate fatty acid transport protein 2 (FATP2), and the selective pharmacological inhibition of FATP2 abrogates the activity of PMN-MDSCs and substantially delays tumor progression (139).